Hylan G-F 20 was safe and effective in knee osteoarthritis and had a relatively low cost-utility ratio
- New Arthritis Drug Offers No Advantage. // HealthFacts;Jul2000, Vol. 25 Issue 7, p4
Presents information on the meloxicam, an anti-inflammatory drug for osteoarthritis which has been approved by the United States Food and Drug Administration in July 2000.
- Postponing knee replacement. Nugent, Jeffrey T. // Arthritis Today;May/Jun99, Vol. 13 Issue 3, p64
Responds to an inquiry about the usage and potency of Synvisc or Hyalgan to treat osteoarthritis. General classification of the drugs as viscosupplements; Similar side effects and allergic reactions; Differences in administration; Skepticism about the viability of the drugs to replace cheaper...
- Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Moreau, M.; Dupuis, J.; Bonneau, N.H.; Desnoyers, M. // Veterinary Record: Journal of the British Veterinary Association;3/15/2003, Vol. 152 Issue 11, p323
The efficacy, tolerance and ease of administration of a nutraceutical, carprofen or meloxicam were evaluated in a prospective, double-blind study on 71 dogs with osteoarthritis. The client-owned dogs were randomly assigned to one of the three treatments or to a placebo control group. The...
- Strengthening bones faster. Dunkin, Mary Anne; Svitil, Kathy // Arthritis Today;Mar/Apr98, Vol. 12 Issue 2, p19
States that the drug alendronate sodium (Fosamax) reduces risk of bone fractures from osteoarthritis. Details on alendronate; Length of time required for drug to produce significant changes in bone density or fracture risk; Indication of Fosamax International Study conducted globally.
- Triple Therapy Equivalent to Enbrel, Study Finds. // Chain Drug Review;7/8/2013, Vol. 35 Issue 11, p49
The article focuses on a study funded by the Department of Veterans Affairs which states that medication developed by pharmaceutical company Amgen Inc. is no more effective than a cocktail of cheaper generic therapies in treating a severe joint disease.
- Erosive Osteoarthritis: Presentation of a Treatment-Resistant Case. Ulusoy, Hasan; Agkõl, Gürkan; Karaca Acet, Günseli; Kaya, Arzu; Kamanli, Ayhan // Turkish Journal of Rheumatology;Mar2011, Vol. 26 Issue 1, p53
Erosive osteoarthritis (EOA) is a progressive disease affecting the interphalangeal joints of the hand. It is also known as an inflammatory form of osteoarthritis. Pain, swelling, redness, warmth and limited function of the hand joints are commonly found in most patients with or without Heberden...
- Use of Rofecoxib Improves Quality of Life in Osteoarthritis Patients. Schnitzer, Thomas; Rose, Verna L. // American Family Physician;7/1/1999, Vol. 60 Issue 1, p252
Presents an abstract of a study on the effectiveness of rofecoxib in relieving the pain and inflammation of osteoarthritis, which was presented at the 62nd National Scientific Meeting of the American College of Rheumatology in July 1999.
- NSAID use in diabetics with joint disease. R.M.D. // Cortlandt Forum;01/25/97, Vol. 10 Issue 1, p122
Recommends the use of aspirin in treating patients with non-insulin-dependent diabetes mellitus and renal insufficiency who suffer from chronic degenerative joint disease. Association of long-term use of acetaminophen with deterioration of renal function.
- Review supports current treatment guidelines for osteoarthritis of the knee. // Modern Medicine;Aug97, Vol. 65 Issue 8, p56
Presents an abstract of `A Systematic Review of Randomized Controlled Trials of Pharmacological Therapy in Osteoarthritis of the Knee, with an Emphasis on Trial Methodology' by T.E. Towheed and M.C. Hochberg `Seminars on Arthritis Rheumatitis' dated April 1997.